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ABSTRACT
The human MICI gene codes for the core protein of a inutili which
is expressed by glandular epithelia and the carcinomas which develop
from these tissues. The core protein is aberrantly glycosylated in cancers,
and some antibodies show specificity in their reactions with the cancer-
associated mutin, which also contains epitopes recognized by "I-tells
from breast and pancreatic cancer patients. For evaluating the potential
use of mucin-reactive antibodies and mucin-based Â¡mmunogens in cancer
patients, a mouse model, expressing the Ml (I gene product PEM
(polymorphic epithelial mucin) as a self antigen, would be extremely
useful. To this end, we have developed transgenic mouse strains express
ing the human Ml'(.'I gene product in a tissue-specific manner. The TG4
mouse strain was established using a 40-kilobase fragment containing
4.5 kilobases of 5' and 27 kilobases of 3' flanking sequence. The TG18
strain was developed using a 10.6-kilobase .S'adÃ¬fragment from the 40-
kilobase fragment; this fragment contained 1.6 kilobases of 5' sequence
and 1.9 kilobases of 3' flanking sequence. Both strains showed tissue
specificity of expression of the MUC1 gene, which was very similar to
the profile of expression seen in human tissues. The antibody SM-3 is
directed to a core protein epitope, which is selectively exposed in breast
cancers and which shows a more restricted distribution on normal human
tissues. It was established that the distribution of the SM-3 epitope
of PEM in the tissues of the transgenic mice is similar to that seen
in humans. The transgenic mouse strains described here should form
the basis for the development of a preclinical model for the evaluation
of PEM-based antigens and of antibodies directed to PEM in cancer
therapy.
INTRODUCTION
Attention has been focused on the epithelial-associated mu-
cins because many antibodies developed against normal or
malignant epithelial cells and their products have been found
to react with these complex molecules (for a review see Ref. l).
One such mucin is produced in abundance by the lactating
mammary gland and expressed by many simple epithelial cells
lining glands or ducts and the adenocarcinomas which develop
from them. The complete amino acid sequence of the core
protein of the mammary mucin has been obtained by gene
cloning and shows the mucin to be a transmembrane protein
with a large extracellular domain made up largely of 20 amino
acid tandem repeats and a cytoplasmic tail of 69 amino acids
(2-4). Since the gene and its expressed product show a high
degree of length polymorphism due to the presence of different
numbers of tandem repeats (2, 5), we have referred to the gene
product as the polymorphic epithelial mucin (2, 6). Partial
complementary DNA clones coding for two gastrointestinal
mucin core proteins (7, 8) and a tracheobronchial mucin-like
protein (9) have recently been isolated and sequenced. We
therefore now refer to the gene as MUC1 to distinguish it from
the other three human mucin genes (which are referred to as
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MUC2, A/Ã•/C3, and MUC4), but we continue to refer to the
product as PEM.2
Although PEM is expressed on both normal and malignant
epithelial cells, the carbohydrate side chains of the cancer-
associated mucin are shorter (10, 11), resulting in the expres
sion of new carbohydrate epitopes and in the exposure of novel
epitopes in the core protein, which show a restricted distribution
on normal cells. Antibodies to PEM can therefore show some
degree of specificity in their reactions with tumors. The anti
body SM-3 (12) reacts with a core protein epitope (13) which
is selectively exposed in breast and other carcinomas (13, 14)
and has been successfully used for imaging ovarian cancer (15).
The difference in glycosylation also results in the exposure of
core protein epitopes (overlapping the SM3 epitope) which are
recognized by T-cells isolated from cancer patients (16, 17),
suggesting that the PEM antigen could be effective in active
specific immunotherapy.
For evaluating drug or toxin conjugates of antibodies to PEM
and for assessing whether the antigen itself may be useful in
the therapy of some adenocarcinomas, it is essential to have a
model system for preclinical studies. In this context, the xeno-
graft model is of limited value, since the antigen is not expressed
on the normal tissues of the mouse and the immune system of
the nude mouse is defective. For testing the immunogenicity
and efficacy of PEM-based immunogens in tumor rejection, we
have developed a syngeneic mouse model where a transplanta-
ble tumor expresses PEM (18). Although this model is useful
for comparing different immunogens, the fact that the PEM
antigen is recognized as foreign limits its use for predicting the
immune response of human subjects where PEM is expressed
as a self antigen. Thus a mouse expressing the MUC1 gene
product as a self antigen in a tissue-specific manner would
provide an extremely important model for preclinical testing of
both antibody conjugates and PEM-based immunogens. With
this in mind we have developed transgenic mouse strains where
PEM is expressed in the same epithelial tissues as in humans.
The glycosylation of PEM can vary with the tissue, resulting
in the production of final mucin products with different anti-
genie profiles. In particular, the epitope recognized by SM3 is
not found on all the expressing tissues. We have therefore also
looked at the reaction of the different tissues with the antibody
SM3. Our results show that, as is seen in humans (12, 14, 19),
the epitope recognized by this antibody shows a more restricted
distribution, suggesting that the glycosylation pattern of PEM
in the tissues of the transgenic mice is similar to that seen in
humans.
MATERIALS AND METHODS
Development of Transgenic Mice Expressing PEM. A cosmid clone
GPEM-1 was isolated from the human genomic library pCOS2EMBL
made from peripheral blood lymphocytes (kindly donated by Dr. A. M.
Frischauf, ICRF, London) (20). The 40-kilobase insert was prepared
by digesting the cosmid DNA, which was prepared with a Quiagen
2The abbreviations to be used are: PEM, polymorphic epithelial mucin; PBS,
phosphate-buffered saline.
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column (Hybaid, Teddington. Middlesex, England) with Sail and Cla\
restriction endonucleases (New England Biolabs, Beverley, MA), which
cut into the vector sequence at about 300 and 400 base pairs, respec
tively, from the insert site. The insert was electroluted from the agarose
gel, ethanol precipitated, redissolved in water, and centrifuged through
a 1-ml Sepharose G25 column. DNA was filter sterilized for injection
by centrifuging it through a 0.22 /MUcellulose acetate spin-x Costar
filter unit using TE buffer made from molecular biology-grade water
(BDH Eastleigh, Hertfordshire, England).
The SacU genomic fragment was prepared by digesting the GPEM-
1 clone and isolating the 10.6-kilobase piece of DNA as described
above.
DNA was diluted to a final concentration of I mg/ml for injection
into the pronuclei of fertilized CBA x C57Blk F, mouse eggs, which
were then tranferred to pseudopregnant CBA x C57 Blk FI females.
All manipulations were as described by Hogan et al. (21). Transgenic
mouse strains derived from the 40-kilobase fragment are referred to as
TG4 and TG5, and that from the Sudi fragment as TG18.
Genomic DNA Isolation and Southern Blot Analysis. Genomic DNA
was prepared from T47D cells (human mammary carcinoma; Ref. 22)
with an Applied Biosystems (Foster City, Ã‡A)340A DNA extractor.
Mouse tail genomic DNA was prepared according to the method of
Hogan el al. (21). Samples (10-15 ng) were digested with the appro
priate restriction endonucleases (New England Biolabs, Beverley, MA)
under conditions recommended by the manufacturer, prior to electro-
phoresis through a 0.7% agarose gel.
Southern blotting onto nylon membranes (Pall Biodyne, Glen Cove,
NY) and subsequent hybridization/washing procedures were carried
out according to the manufacturer's instructions. The human probe
pMUC7, corresponding to ~500 base pairs of tandem repeat domain
(5), was utilized. The probe was labeled using random priming (23) in
the presence of [Â«-"PJdCTP (Amersham International pic) to a specific
activity of >1 x lO'dpm/^g.
RNA Analysis. Total RNA was prepared from tissue culture cells
and mouse mammary gland (lactating and nonlactating) by guanidi-
nium isothiocynate extraction (24), the tissue having first been pulver
ized with a Braun Mikro-dismembranator II (Melsuugen, Germany).
Northern analysis was carried out as previously described (2) using[a-32P]dCTP-labeled probes to the human tandem repeat (pMUC7) and
a mouse mucin probe (pMuclO), corresponding to -1.2 kilobases of 3'
complementary DNA, from the mouse repeat domain to the polyaden-
ylated tail (25). For mapping of the transcriptional start site total RNA
from T47D, ICRF 23 (human embryonic lung fibroblast cell line), TG4,
TG5, and nontransgenic lactating mammary' gland were isolated and
primer extension analysis was carried out as described previously (2).
Staining of Tissue Sections. Transgenic mice (4-6 weeks old or at
lactation) were sacrificed and dissected. Tissues were divided and either
stored in liquid nitrogen prior to RNA extraction or fixed in methacarn
(methanol:chloroform:aceticacid, 60:30:10) and paraffin embedded for
staining. Dewaxed paraffin sections were incubated with 50% fetal calf
serum in PBS for 30 min to prevent nonspecific binding of antibodies.
Blocking solution was then drained off, replaced by neat hybridoma
culture supernatant, and incubated for 60 min at room temperature.
After three 5-min washes in PBS the sections were incubated for l h
with peroxidase-conjugated rabbit anti-mouse immunoglobulin anti-
serum (Dako; diluted 1:50 in PBS with 15% fetal calf serum). The
slides were then washed three to four times in PBS with intermittent
agitation. The substrate solution consisting of 0.03% hydrogen peroxide
in PBS and 1 mg/ml diaminobenzidine (Sigma) was added, and the
reaction was allowed to continue for 5-8 min. After washing in PBS
the slides were counterstained with hematoxylin and mounted in
gelvatol.
RESULTS
Identification of MUCI Transgenic Mice. We have recently
reported the full sequence of the MUCI gene, together with
800 base pairs of 5' flanking sequence (20). The sequence was
obtained from cosmid clones, one of which, GPEM1, was
obtained from a pCos2EMBL library (20). The full insert of
=40 kilobases together with =700 base pairs of vector sequence
could be obtained from GPEM1 by cutting with the enzymes
SaÃŸ and Clal (Fig. 1). This fragment contains the sequences
for the MUCI gene with 4.5 kilobases of 5' and =27 kilobases
of 3' flanking sequences, and was used to develop transgenic
mice. In later experiments a 10.6-kilobase fragment obtained
from a SacU digest of GPEM1 was also successfully used to
develop a PEM-expressing strain of mouse. This fragment
contained only 1.6 kilobases of 5' sequence and 1.9 kilobases
of 3'. Fig. 1 shows diagrammatically the restriction enzyme
sites in the large fragment and the intron-exon structure of the
gene contained within the 10.6-kilobase SacU fragment.
The 40-kilobase or 10.6-kilobase fragments, isolated from
GPEM1, were microinjected into fertilized mouse ova, trans
planted into pseudopregnant mice, and DNA prepared from
tail snips of the litters. The DNA was digested with EcoRl and
analyzed on Southern blots using the probe pMUC7. pMUC7
contains eight of the 60-base pair tandem repeats which make
up a large part of exon 2 of the MUCI gene (see Fig. 1) and no
unique sequence. The mouse gene corresponding to the human
MUCI has recently been cloned (25), and although it also has
been found to contain tandem repeats of 20-21 amino acids,
the sequence is only 56% homologous (at the nucleotide level)
40kbp Insert from . I
GPEM-I |â€”I I I .
10 6Kbp Sacll Insen
Fig. 1. DNA fragments from pCos2EMBL
containing the MUCI gene used for injection
into fertilized eggs. I. 40-kilobase Sail and
Clal fragment; B. 10.6-kilobase Sacll frag
ment; C, intron-exon structure and major fea
tures of the gene. E, EcoRl sites; B. BamHl
sites. A and B are drawn to scale; C is not.
I i
G/C Boxes mn.
j 39bp Signal sequence
] 2 3kbp Tandem Repeal
I 93bp Trans mem bra ne
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A B 20 15 10
â€”¿9.4kb
â€”¿6.5kb
Fig. 2. Southern blot of EcoR\ digest of DNA from the transgenic mouse
strains TO 18 (Â¡MMA ) and TG4 (Lane B) probed with pruUC?. Different amounts
of an Â£VoRIdigest of the pcos2EMBL cosmid were applied in the other lanes.
Numbers along the top. numbers of copies which would have to be present in the
20 ^ig of total genomic DNA applied to Lanes A and B to give the signal shown
in the cosmid digests.
to that seen in the human gene. pMUC7 therefore does not
hybridize to the mouse gene and can be used to selectively
detect the presence of the human MUC1 in the mouse genome.
Using the pMUC7 probe, three mice carrying the 40-kilobase
fragment in their genome were identified, one of which did not
transmit. The other two, TG4 and TG5, did show transmission
and were analyzed further. Two mice were identified as carrying
the 10.6-kilobase fragment, and one of these (TGI8) was also
analyzed.
Fig. 2 shows a Southern blot of EcoRl digests of DNA from
two mouse strains (TG4 and TG 18) as well as different concen
trations of the cosmid clone GPEM1, also digested with EcoRl.
The EcoR\ fragment from the TG4 mouse strain is the same
size as the fragment released by EcoRl digestion from GPEM1
(8.3 kilobases), while in the case of the TGI 8 mice derived with
the 10.6-kilobase Sacll fragment, the EcoRl fragment reactive
with the pMUC7 probe is around 10.6 kilobases. [The same
size fragment shows a different mobility when run as picograms
of pure DNA (cosmid digests) or when digested from 15 ng of
genomic DNA.] A comparison of the intensity of the signals
from the main band in each of the DNA digests indicates that
the copy number is low, of the order of 1-3 in both lines. There
is only one EcoRl site in the 10.6-kilobase Sacll fragment,
indicating that there must be at least two copies integrated in
tandem in this line, to produce the dominant band of 10.6
kilobases in the EcoRl digest. The faint bands observed in the
digests probably correspond to a fragment containing some
flanking host DNA together with the part of the PEM gene
including the tandem repeat domain. The pattern of bands seen
in Fig. 2 was consistently observed in progeny obtained over
four generations, suggesting that the gene was integrated into
both strains at a single site.
Developmental Regulation of Expression of the Transgene.
Immunohistochemical analysis of a range of human tissues has
shown PEM to be expressed by several epithelial cell types (see
Table 1). In the mammary gland, however, there is a dramatic
increase in expression seen at lactation. A similar increase in
staining with PEM-specific antibodies was also seen in the
lactating mammary glands of the TG4 and TGI8 mice but not
in the TG5 mice. The increase in expression of PEM could be
seen at the RNA level, and Fig. J>Ashows a Northern blot of
RNA extracted from the sources indicated in the legend, probed
with pMUC7. Although expression can clearly be detected in
the lactating gland of TG4 mice (Fig. 3/Ã•,Lane 3), the level in
the nonlactating females (Fig. 3/4, Lane 4) is below that detect
able by this technique. A similar result was seen with the TGI8
mice (data not shown), but in the TG5 strain, where no positive
Table 1 Comparison of expression of the MVCI gene in humans and in
transgenic mice detected by immunohistochemical staining
All neuroectodermal and mesenchymal tissues and cells of the lymphoreticular
system showed no reaction with the antibodies.
TissueBreastResting
breast
Acini andductsLactating
breast
Acini and ductsHMFG1
HMFG2SM3TG4
TG4TG4Human"
mice Human" mice Human*mice+f+
+ +--+
+ + -/+ -/+
Female reproductive system
Ovary
Surface epithelium,
oocytes, follicular
epithelium
Interstitial cells ND
Fallopian tubes
Epithelium +
Uterus
Endometrium and endo- +
cervical uterine glands
Myometrium
Male reproductive system
Testis
Capsule â€”¿
Sertoli and Leidig cells -
Spermatids
Spermatocytes
Epidydimis''
Columnar epithelium +
with stercocilia
Sperm mass ND
Interstitial tissue ND
Urinary system
Kidney
Glomeruli and proximal â€”¿
tubules
Distal tubules and col- +
lecting ducts
Gastrointestinal tract
Esophagus
Squamous epithelium +
Stomach
Mucus-secreting cells
Mucus neck cells ND
Parietal cells +
Peptic cells +
Small intestine
Enterocytes â€”¿
Goblet cells ND
Pancriatico-biliary system
PancreasAcinar cells'
Male +
Female -
Acinar ducts +
Excretory ducts ND
Islets of Langerhans
Liver
Hepatocytes â€”¿
Bile ducts +
Respiratory system
Lung
Respiratory epithelium +
Clara cells ND
Pneumocytes +
ND
ND
ND
ND
ND
ND
/- ND
ND
ND
(T)-
ND -/
ND
ND
ND
" See Ref. 28. For lactating gland see Ref. 14.
*SeeRefs. 14 and 19.
' +. uniform +ve: â€”¿,uniform â€”¿ve;-t-/â€”,focally positive but heterogenous in
distribution: â€”¿/+. very weak, barely detectable; ND, not done.
' For staining of epididymis see Ref. 38.
' Refers to intracytoplasmic staining.
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Table I Continued
Tissue
HMFGl HMFG2 SM3
TG4 TG4 TG4
Human" mice Human" mice Human* mice
Salivary glands
Parotid gland
Serous acini +
Excretory ducts ND
Intercalated ducts +
ND
Sublingual gland
Mucus acini
Excretory ducts
Intercalated ducts
Myoepithelial cells
ND +/- ND
ND
Submandibular gland
Mucus acini -t-
Serous acini +
Excretory ducts N D
Intercalated ducts +
ND
staining with antibodies was seen even on the lactating gland,
expression could not be detected in either the lactating or
nonlactating glands (Fig. 3A, Lanes 5 and 6). Using primer
extension analysis, we were able to show that transcription of
the human PEM gene began from the same start site as seen in
humans (see Fig. 4).
To compare the expression of the transgene with the endog
enous gene, a probe specific for the mouse gene (pMuclO) was
used to detect mRNA transcribed from the mouse Mud gene
(25). Fig. 3Ã„shows that using the mouse probe, a transcript of
2.3 kilobases was detected in RNA from lactating mammary
glands of both transgenic and nontransgenic mice, but not in
the human breast cancer cell line T47D or the human fibroblast
strain ICRF23. Expression of the mouse mucin was not detect
able on Northern blots of the nonlactating mammary gland.
Thus, the increased level of expression of the human gene at
lactation followed the increased level of expression of the mouse
gene seen at this stage of development.
Tissue-specific Expression of the MUCI Gene Product in
Transgenic Mice. Many of the antibodies developed against
human PEM react with core protein epitopes found in the
tandem repeat domain between potential glycosylation sites.
These epitopes are not present on the mouse mucin because the
sequence of the tandem repeat is different, which probably
explains why this region is so immunodominant in the rodent
in the production of both monoclonal antibodies and polyclonal
antisera. To analyze the level of expression of the transgene,
therefore, a polyclonal antiserum and the monoclonal antibod
ies HMFG-1 and HMFG-2 (26), directed to abundant core
protein epitopes (13, 27), were used. A similar profile of expres
sion was seen with the polyclonal antiserum and with the
monoclonal antibodies HMFG-1 and HMFG-2. Zotter and
colleagues (28) have made an extensive survey of the expression
of PEM by human tissues, using a bank of monoclonal anti
bodies, including HMFG-1 and HMFG-2. We have therefore
compared our results, obtained from staining the tissues of
transgenic mice with these two antibodies, with those of Zotter
and colleagues. The detailed comparison for the TG4 strain is
listed in Table 1, which shows the results of analyzing five
males, five nonlactating females, and five lactating females of
the TG4 strain. A similar staining pattern was seen with the
TGI8 mice. Since in the TG5 mice expression was not seen in
the lactating mammary gland (although it was seen in the
stomach and kidney), these mice were not analyzed in detail.
The results of staining the various tissues of the TG4 mice
with HMFG-1 and HMFG-2 showed that PEM expression was
limited to epithelial tissues, and the pattern of expression
closely resembled the pattern of expression seen in normal
human tissues (Table 1 and Fig. 5). Mucin expression was
mainly seen in epithelial cells lining glands or ducts. In most
glandular epithelia such as the mammary gland and the salivary
gland, PEM was expressed on the luminal surface (Fig. 5/1, A,
and A").However, in the pancreas of female mice it was difficult
to ascertain whether the expression on the luminal aspect of
the acinar cell reflected acinar expression or expression by the
intercalating duct (see Fig. 5G). In the male mice, however,
intracytoplasmic staining of the acinar cells was seen. As in
humans the tissues showing the strongest staining with HMFG-
1 and HMFG-2 were the lactating mammary gland (Fig. 5, A
and B), the proximal and collecting ducts of the kidney, the
peptic cells of the stomach (Fig. 5, // and /), and lung epithelial
cells (Fig. 5, D-F). The tissues which did not appear to express
PEM were also similar in the TG4 mice and humans. These
were the small and large intestine (occasional goblet cells in the
TG4 mice showed positive staining), ovary, mesenchyme (blood
vessels, all muscle types, connective tissue, including fat), the
lymphoreticular system, including spleen, lymph nodes, and
thymus (epithelioid cells in the medulla were positive), the
central nervous system, and the peripheral nervous system.
There were some minor differences in the staining patterns
of HMFG-1 and HMFG-2 in the transgenic mice as compared
to that reported by Zotter and colleagues for human tissues.
Thus we found some staining of the squamous epithelium of
the ectocervix in the female transgenic mice and in the sper-
matocytes and spermatids, which was not reported by Zotter
and colleagues for the corresponding human tissue. Moreover,
the squamous epithelium of the human esophagus was reported
to be stained by HMFG-2, whereas in the mouse there was a
clear demarcation between the negative staining of the esoph
agus and the positive staining of the stomach in the transgenic
mouse (Fig. 57). Also, some staining of the human small and
large intestine and of the bile ducts was reported by Zotter and
colleagues, although this was not seen by Girling and colleagues
(14, 19) using the same antibodies (19). These may reflect
minor differences in the pattern of expression of the MUCI
gene in humans and mice. However, minor quantitative differ
ences between the two studies could reflect differences in the
fixatives used and the time after death before tissues were
processed.
Reaction of the Antibody SM3 with the Human Mucin Ex
pressed on Tissues of TG4 Mice. Glycosylation of PEM in
humans can vary with the tissue where it is expressed, thus
resulting in differences in the antigenic profile of the final
mucin product. In particular, core protein epitopes recognized
by the antibody SM3 are exposed where the carbohydrate side
chains are short or masked where the side chains are longer
and/or branched (12, 13). Since the SM3 epitope is selectively
exposed in tumors (14) and may overlap a T-cell epitope (17),
its accessibility in the mucin molecules produced by the different
tissues is of particular interest. To get some idea as to whether
the differences in glycosylation detected by SM3 reactivity
which were observed in humans were also seen in the transgenic
mice, the reactivity of the antibody SM3 with the different
tissues was also examined. Table 1 shows the results of this
analysis and for comparison lists the findings of Girling and
colleagues (14, 19), who examined the expression of the SM-3
epitope on normal human tissues. Again, the correlation with
SM3 staining of human tissues was good, and in particular the
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lack of staining of the lactating mammary gland (Fig. 5C) was
very striking, since this tissue produces high levels of PEM. As
with the human tissues, the most consistent expression of the
SM3 epitope was seen in the lung (Fig. 5F), the kidney, the
stomach, and the fallopian tube. Other epithelial tissues showed
weak or focal staining with the antibody (see Table 1). The
weak focal staining seen in the intercalating ducts of the salivary
gland of the transgenic mouse was not reported by Girling and
colleagues for the corresponding human tissue.
DISCUSSION
In this report, we describe the development of transgenic
mouse strains which express the human MUCI gene product
PEM in a tissue-specific manner. The pattern of expression in
the tissues of the adult transgenic mice shows remarkably good
agreement with the pattern of expression of the gene seen in
human tissues. The comparison was made on the basis of
immunohistochemical data using antibodies to the core protein
epitopes recognized by HMFG-1 and HMFG-2. The immuno
histochemical analysis also showed that the human gene was
found to be dramatically up-regulated in the lactating mammary
gland, and the increased expression could be detected for both
the mouse and the human gene at the RNA level.
There are minor differences in the tissue specificity of expres
sion seen in the transgenic mice and in humans. These could
reflect differences in transcription factors present and active in
tissues in question. A complete survey of the tissue specificity
of expression of the mouse homologue could help shed light on
this possibility, and such a study is under way. It is also likely
that where expression is seen in the mouse and not in the
corresponding human tissue, the more rapid time of processing
which was possible with the mouse tissue could be an important
factor. Overall, however, the expression of the MUCI gene in
the transgenic mouse parallels very closely the expression of
the gene seen in the human tissues. Of particular interest is the
observation that PEM is expressed cytoplasmically in the acinar
cells of the pancreas of the male transgenics but only on the
luminal aspect of these cells in the female transgenics. A more
detailed analysis of the expression of MUCI in the human
pancreas is warranted to see if expression in this tissue could
be influenced by the hormonal environment.
Although the MUCI gene product is expressed in most
glandular epithelia, the glycosylation of the core protein can
vary widely in different tissues, resulting in differences in the
antigenic profile of the final mucin product. The core protein
epitope (pro-asp-thr-arg-pro) recognized by the antibody SM-3
lies between potential glycosylation sites within the tandem
GCAT12345
â€”¿89bp
Fig. 4. Transcriptional start site of human PEM gene in lactating mammary
gland of TG4 mouse, mapped by primer extension. A synthetic oligonucleotide
(21 mer) complementan to nucleotides +73 to +93 of (he human PEM gene was
end labeled and used as primer with reverse transcriptase and total RNA from
T47D cells (Lane /). lactating mammary gland of TG5 mice (Lane 2). lactating
mammary gland of nontransgenic mouse (Lane 3). lactating mammary gland of
TG4 mouse (Â¡Mne4), and ICRF-23 cells (Ijtne 5). The products were separated
on a 6% sequencing gel. showing the primary extension product to be 89 base
pairs, indicating that the transcriptional start site is 68 base pairs 5' to the ATG
translational start site. (Due to a numerical error this was reported to be 72 base
pairs in Ref. 2.)
repeat sequence and is selectively exposed when the carbohy
drate side chains are short (13). Although the epitope is abun
dantly expressed in breast and other carcinomas, it shows a
more restricted distribution on normal tissues than other core
protein epitopes, such as those recognized by antibodies
HMFG-1 and HMFG-2 (14). It was important therefore to
ascertain whether the distribution of the SM-3 epitope on the
transgenic mouse tissues showed the same tissue distribution
as in humans. Immunohistochemical analysis of the transgenic
mouse tissues showed that the profile of SM-3 reactivity did
indeed resemble that seen by Girling and colleagues in humans.
This suggests that glycosylation patterns in the mouse tissues
resemble those seen in the human and that the tissue specificity
of expression applies not merely to the expression of the core
protein but to the antigenic profile of the final mucin product.
It would seem, therefore, that the transgenic mouse expressing
the human MUCI gene will indeed provide an appropriate
preclinical model for assessing the toxicity of conjugates of
antibodies directed to PEM and for investigating the immune
response to antigens based on PEM.
Fig. 3. Northern blot of total RNA from
transgenie and nontransgenic mammary gland
probed with pMUC7 specific for the human
PEM (A) or pMuclO specific for the mouse
PEM (A). Fifteen ^g of total RNA from the
cells or tissues indicated were subject to gel
eleetrophoresis and blotted onto Biodync
membranes (see "Materials and Methods") be
fore probing with pMUC7 or pMUC'10. Lanes
1, human breast cancer cell line T47D; Lanes
2, human fibroblast strain. ICRF-23; Lanes 3,
TG4 lactating mammary gland: Â¡Mnes4, TG4,
nonlactating mammary gland: Lanes 5, TG5.
nonlactating mammary gland: Â¡Mnes6. TG5.
lactating mammary gland: Lanes 7. nontrans
genic mouse lactating mammary gland.
4.3kbâ€”|
â€”¿2.3kb
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Fig. S. Immunohistochemical staining of
tissues from the transgenic mouse strain TG4
using antibodies HMFG-I (A, D, G, J),
HMFG-2 (B, E, H, I, K, L), and SM3 (C, F).
Ã•-C, lactating mammary gland; D-F, lung; G.
pancreas of a female TG4 mouse; H. stomach;
/. stomach/esophageal junction: J. fallopiantube: A', salivary gland: /. thymus.
V NÂ»
'*â€¢-. * Â«i \ fc
In addition to establishing their potential as appropriate
recipients for antibodies and antigens, the tissue-specific expres
sion seen in the transgenic mice described here suggests that
the regulatory sequences required for tissue-specific expression
of PEM are close to the coding sequences. The TG4 mouse was
developed using a 40-kilobase genomic fragment, but the TGI8
mouse, which showed a similar tissue specificity in expression,
contained only a 10.6-kilobase fragment, 1.6 kilobases of which
were 5' flanking sequences. Although it is possible that se
quences within the introns or 3' to the gene may be involved in
the regulation of tissue-specific expression, there are many cases
where tissue-specific expression of a reporter transgene has
been obtained with only a limited amount of 5' flanking se
quence (29-37). We have been able to show tissue-specific
expression of a reporter gene in tissue culture cells using less
than 1.6 kilobases of 5' flanking sequence of the PEM gene,1
and we are now developing transgenic mice with these con
structs. Should it be possible to obtain tissue-specific expression
from a defined 5' flanking sequence, this sequence could be
used to direct expression of an oncogene in a double transgenic
derived from the TG4 or TGI8 strain. Such mice, which would
3 D. Wilson, personal communication.
be expected to develop tumors in PEM-expressing tissues,
would provide an excellent model for examining the use of
PEM-based antibodies and antigens in cancer therapy.
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